2024-09-282025-09-302025-09-30false09237585GERMAN MEDICAL LIMITED2026-10-13falseiso4217:GBPxbrli:pure092375852024-09-27092375852025-09-30092375852024-09-282025-09-30092375852023-09-28092375852024-09-27092375852023-09-292024-09-2709237585bus:SmallEntities2024-09-282025-09-3009237585bus:AuditExempt-NoAccountantsReport2024-09-282025-09-3009237585bus:FullAccounts2024-09-282025-09-3009237585bus:PrivateLimitedCompanyLtd2024-09-282025-09-3009237585core:WithinOneYear2025-09-3009237585core:AfterOneYear2025-09-3009237585core:WithinOneYear2024-09-2709237585core:AfterOneYear2024-09-2709237585core:ShareCapital2025-09-3009237585core:SharePremium2025-09-3009237585core:RevaluationReserve2025-09-3009237585core:OtherReservesSubtotal2025-09-3009237585core:RetainedEarningsAccumulatedLosses2025-09-3009237585core:ShareCapital2024-09-2709237585core:SharePremium2024-09-2709237585core:RevaluationReserve2024-09-2709237585core:OtherReservesSubtotal2024-09-2709237585core:RetainedEarningsAccumulatedLosses2024-09-2709237585core:LandBuildings2025-09-3009237585core:PlantMachinery2025-09-3009237585core:Vehicles2025-09-3009237585core:FurnitureFittings2025-09-3009237585core:OfficeEquipment2025-09-3009237585core:NetGoodwill2025-09-3009237585core:IntangibleAssetsOtherThanGoodwill2025-09-3009237585core:ListedExchangeTraded2025-09-3009237585core:UnlistedNon-exchangeTraded2025-09-3009237585core:LandBuildings2024-09-2709237585core:PlantMachinery2024-09-2709237585core:Vehicles2024-09-2709237585core:FurnitureFittings2024-09-2709237585core:OfficeEquipment2024-09-2709237585core:NetGoodwill2024-09-2709237585core:IntangibleAssetsOtherThanGoodwill2024-09-2709237585core:ListedExchangeTraded2024-09-2709237585core:UnlistedNon-exchangeTraded2024-09-2709237585core:LandBuildings2024-09-282025-09-3009237585core:PlantMachinery2024-09-282025-09-3009237585core:Vehicles2024-09-282025-09-3009237585core:FurnitureFittings2024-09-282025-09-3009237585core:OfficeEquipment2024-09-282025-09-3009237585core:NetGoodwill2024-09-282025-09-3009237585core:IntangibleAssetsOtherThanGoodwill2024-09-282025-09-3009237585core:ListedExchangeTraded2024-09-282025-09-3009237585core:UnlistedNon-exchangeTraded2024-09-282025-09-3009237585core:MoreThanFiveYears2024-09-282025-09-3009237585core:Non-currentFinancialInstruments2025-09-3009237585core:Non-currentFinancialInstruments2024-09-2709237585dpl:CostSales2024-09-282025-09-3009237585dpl:DistributionCosts2024-09-282025-09-3009237585core:LandBuildings2024-09-282025-09-3009237585core:PlantMachinery2024-09-282025-09-3009237585core:Vehicles2024-09-282025-09-3009237585core:FurnitureFittings2024-09-282025-09-3009237585core:OfficeEquipment2024-09-282025-09-3009237585dpl:AdministrativeExpenses2024-09-282025-09-3009237585core:NetGoodwill2024-09-282025-09-3009237585core:IntangibleAssetsOtherThanGoodwill2024-09-282025-09-3009237585dpl:GroupUndertakings2024-09-282025-09-3009237585dpl:ParticipatingInterests2024-09-282025-09-3009237585dpl:GroupUndertakingscore:ListedExchangeTraded2024-09-282025-09-3009237585core:ListedExchangeTraded2024-09-282025-09-3009237585dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-09-282025-09-3009237585core:UnlistedNon-exchangeTraded2024-09-282025-09-3009237585dpl:CostSales2023-09-292024-09-2709237585dpl:DistributionCosts2023-09-292024-09-2709237585core:LandBuildings2023-09-292024-09-2709237585core:PlantMachinery2023-09-292024-09-2709237585core:Vehicles2023-09-292024-09-2709237585core:FurnitureFittings2023-09-292024-09-2709237585core:OfficeEquipment2023-09-292024-09-2709237585dpl:AdministrativeExpenses2023-09-292024-09-2709237585core:NetGoodwill2023-09-292024-09-2709237585core:IntangibleAssetsOtherThanGoodwill2023-09-292024-09-2709237585dpl:GroupUndertakings2023-09-292024-09-2709237585dpl:ParticipatingInterests2023-09-292024-09-2709237585dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-292024-09-2709237585core:ListedExchangeTraded2023-09-292024-09-2709237585dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-292024-09-2709237585core:UnlistedNon-exchangeTraded2023-09-292024-09-2709237585core:NetGoodwill2025-09-3009237585core:IntangibleAssetsOtherThanGoodwill2025-09-3009237585core:LandBuildings2025-09-3009237585core:PlantMachinery2025-09-3009237585core:Vehicles2025-09-3009237585core:FurnitureFittings2025-09-3009237585core:OfficeEquipment2025-09-3009237585core:AfterOneYear2025-09-3009237585core:WithinOneYear2025-09-3009237585core:ListedExchangeTraded2025-09-3009237585core:UnlistedNon-exchangeTraded2025-09-3009237585core:ShareCapital2025-09-3009237585core:SharePremium2025-09-3009237585core:RevaluationReserve2025-09-3009237585core:OtherReservesSubtotal2025-09-3009237585core:RetainedEarningsAccumulatedLosses2025-09-3009237585core:NetGoodwill2024-09-2709237585core:IntangibleAssetsOtherThanGoodwill2024-09-2709237585core:LandBuildings2024-09-2709237585core:PlantMachinery2024-09-2709237585core:Vehicles2024-09-2709237585core:FurnitureFittings2024-09-2709237585core:OfficeEquipment2024-09-2709237585core:AfterOneYear2024-09-2709237585core:WithinOneYear2024-09-2709237585core:ListedExchangeTraded2024-09-2709237585core:UnlistedNon-exchangeTraded2024-09-2709237585core:ShareCapital2024-09-2709237585core:SharePremium2024-09-2709237585core:RevaluationReserve2024-09-2709237585core:OtherReservesSubtotal2024-09-2709237585core:RetainedEarningsAccumulatedLosses2024-09-2709237585core:NetGoodwill2023-09-2809237585core:IntangibleAssetsOtherThanGoodwill2023-09-2809237585core:LandBuildings2023-09-2809237585core:PlantMachinery2023-09-2809237585core:Vehicles2023-09-2809237585core:FurnitureFittings2023-09-2809237585core:OfficeEquipment2023-09-2809237585core:AfterOneYear2023-09-2809237585core:WithinOneYear2023-09-2809237585core:ListedExchangeTraded2023-09-2809237585core:UnlistedNon-exchangeTraded2023-09-2809237585core:ShareCapital2023-09-2809237585core:SharePremium2023-09-2809237585core:RevaluationReserve2023-09-2809237585core:OtherReservesSubtotal2023-09-2809237585core:RetainedEarningsAccumulatedLosses2023-09-2809237585core:AfterOneYear2024-09-282025-09-3009237585core:WithinOneYear2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:CostValuation2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-282025-09-3009237585core:Non-currentFinancialInstrumentscore:CostValuation2025-09-3009237585core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-09-3009237585core:Non-currentFinancialInstrumentscore:CostValuation2024-09-2709237585core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-2709237585core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-2709237585bus:Director12024-09-282025-09-3009237585core:FurnitureFittingsToolsEquipment2024-09-2709237585core:FurnitureFittingsToolsEquipment2024-09-282025-09-3009237585core:FurnitureFittingsToolsEquipment2025-09-30092375851bus:Director12024-09-27092375851bus:Director12024-09-282025-09-30092375851bus:Director12025-09-30092375852024-09-27092375852024-09-282025-09-30092375852025-09-30

GERMAN MEDICAL LIMITED

Registered Number
09237585
(England and Wales)

Unaudited Financial Statements for the Period ended
30 September 2025

GERMAN MEDICAL LIMITED
Company Information
for the period from 28 September 2024 to 30 September 2025

Director

FAHMY-IBRAHIM, Hossam, Dr

Company Secretary

ELSHIMI, Samaa

Registered Address

Ramsay Brown Llp The Brentano Suite
Solar House, 915 High Road
North Finchley
N12 8QJ

Registered Number

09237585 (England and Wales)
GERMAN MEDICAL LIMITED
Balance Sheet as at
30 September 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets36,0693,736
6,0693,736
Current assets
Debtors41,779,8821,706,880
Cash at bank and on hand416,77065,872
2,196,6521,772,752
Creditors amounts falling due within one year5(419,295)(77,901)
Net current assets (liabilities)1,777,3571,694,851
Total assets less current liabilities1,783,4261,698,587
Creditors amounts falling due after one year6(16,882)(30,455)
Provisions for liabilities7(1,530)(1,064)
Net assets1,765,0141,667,068
Capital and reserves
Called up share capital22
Profit and loss account1,765,0121,667,066
Shareholders' funds1,765,0141,667,068
The financial statements were approved and authorised for issue by the Director on 13 October 2026, and are signed on its behalf by:
FAHMY-IBRAHIM, Hossam, Dr
Director
Registered Company No. 09237585
GERMAN MEDICAL LIMITED
Notes to the Financial Statements
for the period ended 30 September 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Finance costs
Finance costs charged to the profit or loss include interest expense calculated using the effective interest method from FRS 102:11, finance charges on finance leases, and exchange differences on foreign currency borrowings where these are treated as an adjustment to interest costs.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Fixtures and fittings25
Office Equipment25
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20252024
Average number of employees during the year22
3.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 28 September 244,3435,95110,294
Additions1,0002,9983,998
At 30 September 255,3438,94914,292
Depreciation and impairment
At 28 September 243,5822,9766,558
Charge for year3151,3501,665
At 30 September 253,8974,3268,223
Net book value
At 30 September 251,4464,6236,069
At 27 September 247612,9753,736
4.Debtors: amounts due within one year

2025

2024

££
Amounts owed by associates and joint ventures / participating interests341,3281,096,627
Other debtors1,437,557610,253
Prepayments and accrued income997-
Total1,779,8821,706,880
5.Creditors: amounts due within one year

2025

2024

££
Taxation and social security416,86176,701
Accrued liabilities and deferred income2,4341,200
Total419,29577,901
6.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts16,88230,455
Total16,88230,455
7.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)1,5301,064
Total1,5301,064
8.Directors advances, credits and guarantees

Brought forward

Amount advanced

Amount repaid

Carried forward

££££
FAHMY-IBRAHIM, Hossam, Dr610,2541,051,451586,8961,074,809
610,2541,051,451586,8961,074,809
As at year-end the director owed the company £1,074,809 (2024: £610,254). Included in the amount owed to the company by the directors is interest totalling £18,746 charged at the official HM Revenue & Customs rate.
9.Related party transactions
Included in other debtors due within one year is an amount of £341,328 (2024: £1,096,627) owed by connected companies. These companies are connected by virtue of the directors.